Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

OTLK

Outlook Therapeutics Inc

Dec 08 • 04:00PM ET

0.4263

Dollar change -0.0159
Percentage change -3.60	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.25	Insider Own	49.37%	Shs Outstand	227.31M	Perf Week	-9.84%
Market Cap	110.94M	Forward P/E	-	EPS next Y	-0.16	Insider Trans	0.00%	Shs Float	131.75M	Perf Month	-14.74%
Income	-60.34M	PEG	-	EPS next Q	-0.06	Inst Own	10.59%	Short Float / Ratio	15.59% / 2.64	Perf Quarter	101.56%
Sales	0.00M	P/S	-	EPS this Y	22.58%	Inst Trans	-2.76%	Short Interest	20.54M	Perf Half Y	-75.36%
Book/sh	-0.02	P/B	-	EPS next Y	33.33%	ROA	-145.33%	Target Price	3.92	Perf Year	-57.79%
Cash/sh	0.13	P/C	3.29	EPS next 5Y	-	ROE	-827.71%	52W Range	0.20 - 2.03	Perf YTD	-60.53%
Dividend	-	P/FCF	-	EPS past 5Y	53.55%	ROI	-	52W High	-79.00%	Beta	0.27
Dividend %	-	Quick Ratio	0.86	Sales past 5Y	15.96%	Gross Margin	-	52W Low	112.94%	ATR	0.04
Employees	17	Current Ratio	0.86	Sales Q/Q	-	Oper. Margin	0.00%	RSI (14)	45.71	Volatility	7.08% 7.71%
Optionable	No	Debt/Eq	-	EPS Q/Q	-1.13%	Profit Margin	-	Rel Volume	0.11	Prev Close	0.44
Shortable	Yes	LT Debt/Eq	-	Earnings	Aug 14 BMO	Payout	-	Avg Volume	7.77M	Price	0.43
Recom	2.50	SMA20	-5.00%	SMA50	2.32%	SMA200	-58.05%	Volume	889,442	Change	-3.60%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-31-23	Downgrade	H.C. Wainwright	Buy → Neutral	$5 → $1
Aug-31-23	Downgrade	Chardan Capital Markets	Buy → Neutral
Aug-30-23	Downgrade	Guggenheim	Buy → Neutral
Aug-30-23	Downgrade	CapitalOne	Overweight → Equal Weight
Aug-30-23	Downgrade	Cantor Fitzgerald	Overweight → Neutral	$4.50 → $1
Aug-30-23	Downgrade	BTIG Research	Buy → Neutral
Jul-13-23	Initiated	CapitalOne	Overweight	$5
Apr-03-23	Initiated	Guggenheim	Buy	$5
Feb-06-23	Initiated	Cantor Fitzgerald	Overweight	$4
Oct-31-22	Initiated	BTIG Research	Buy	$7
Sep-13-22	Initiated	Chardan Capital Markets	Buy	$10
Sep-11-19	Initiated	Ladenburg Thalmann	Buy	$9
May-16-19	Initiated	Oppenheimer	Outperform	$12
Apr-22-19	Initiated	Ascendiant Capital Markets	Buy

Show Previous Ratings

Dec-06-23 08:05AM	Outlook Therapeutics Announces Strategic Organizational Realignment (GlobeNewswire)
Nov-27-23 08:05AM	Outlook Therapeutics Announces Receipt of Type A Meeting Minutes and Reiterates Regulatory Path Forward for ONS-5010 (GlobeNewswire)
06:30AM	OTLK INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Outlook Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Case (GlobeNewswire)
Nov-15-23 02:04PM	OTLK STOCKHOLDERS: Contact Robbins LLP for Information About Your Rights Against Outlook Therapeutics, Inc. (Business Wire)
Nov-14-23 08:05AM	Outlook Therapeutics Adds Global Commercial Expertise with Appointment of Jedd Comiskey as Senior VP - Head of Europe (GlobeNewswire) +8.83%
08:52AM	Loading…
Nov-09-23 08:52AM	12 Best Day Trading Stocks To Buy (Insider Monkey) -11.00%
Nov-02-23 08:05AM	Outlook Therapeutics Provides Update on Type A Meetings with FDA (GlobeNewswire) -46.24%
Nov-01-23 08:05AM	Outlook Therapeutics to Present at Guggenheim's 5th Annual Inflammation, Neurology & Immunology (INI) Conference (GlobeNewswire) +5.40%
Oct-17-23 05:22PM	Outlook Therapeutics Investors: Company Investigated by the Portnoy Law Firm (GlobeNewswire) +14.51%
Oct-11-23 05:49PM	Outlook Therapeutics Investors: Company Investigated by the Portnoy Law Firm (GlobeNewswire)
Sep-29-23 08:05AM	Outlook Therapeutics Requests Type A Meeting With FDA (GlobeNewswire)
Sep-21-23 08:05AM	Outlook Therapeutics® to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference (GlobeNewswire)
Sep-05-23 08:05AM	Outlook Therapeutics® to Present at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-31-23 10:15AM	Biotech Stock Roundup: FGEN Down on Study Failure, BMY Drug's Label Expansion & More (Zacks) -15.08%
Aug-30-23 06:11AM	US FDA declines to approve Outlook Therapeutics' eye disease drug (Reuters) -80.96%
06:00AM	Loading…
06:00AM	Outlook Therapeutics® Provides Regulatory Update on FDA Review of ONS-5010 / LYTENAVA (bevacizumab-vikg) for the Treatment of Wet AMD (GlobeNewswire)
Aug-28-23 11:47AM	Outlook Therapeutics (OTLK): A Deep Dive into its Overvalued Status (GuruFocus.com) +10.34%
Aug-14-23 09:55AM	Should You Buy Outlook Therapeutics (OTLK) Ahead of Earnings? (Zacks)
08:05AM	Outlook Therapeutics® Reports Financial Results for Third Quarter Fiscal Year 2023 and Reiterates Key Anticipated Near-Term Milestones (GlobeNewswire)
Aug-01-23 08:45AM	Outlook Therapeutics® to Present at the BTIG Virtual Biotechnology Conference 2023 (GlobeNewswire)
Jun-11-23 08:45AM	When Will Outlook Therapeutics, Inc. (NASDAQ:OTLK) Turn A Profit? (Simply Wall St.)
Jun-06-23 01:59PM	Why Shares of Outlook Therapeutics Rose Tuesday (Motley Fool)
May-15-23 08:05AM	Outlook Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2023 and Provides Corporate Update (GlobeNewswire)
Apr-27-23 08:05AM	Outlook Therapeutics® to Present at the H.C. Wainwright BioConnect Investor Conference (GlobeNewswire)
Apr-10-23 11:43AM	Outlook Therapeutics, Inc.'s (NASDAQ:OTLK) top owners are individual investors with 37% stake, while 27% is held by private equity firms (Simply Wall St.)
Mar-13-23 07:00AM	Outlook Therapeutics® Confirms It Has No Exposure to Silicon Valley Bank (GlobeNewswire)
Feb-14-23 08:05AM	Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2023 and Provides Corporate Update (GlobeNewswire)
Feb-07-23 08:05AM	Outlook Therapeutics® to Present at the SVB Securities Global Biopharma Conference (GlobeNewswire)
Jan-19-23 08:05AM	Outlook Therapeutics® Strengthens Medical Affairs and Commercial Expertise with Appointments of Surendra Sharma, MD, Senior Vice President of Medical Affairs and Glen Olsheim, Executive Director of Commercial Excellence (GlobeNewswire)
Jan-11-23 01:00PM	JTC Team to Host the Virtual Investor 2023 Companies to Watch Event on January 17th, 18th, and 19th (ACCESSWIRE)
08:05AM	Loading…
Jan-09-23 08:05AM	Outlook Therapeutics® to Present at the Virtual Investor 2023 Companies to Watch Event (GlobeNewswire)
Jan-02-23 07:31AM	Breakeven On The Horizon For Outlook Therapeutics, Inc. (NASDAQ:OTLK) (Simply Wall St.)
Dec-29-22 09:05AM	Outlook Therapeutics® Reports Financial Results for Fiscal Year 2022 and Provides Corporate Update (GlobeNewswire) +5.94%
Dec-23-22 09:00AM	Outlook Therapeutics® Enters Definitive Agreement for $31.8 Million Unsecured Convertible Promissory Note (GlobeNewswire) +21.81%
06:00AM	Outlook Therapeutics Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
Dec-22-22 08:05AM	Outlook Therapeutics® Announces Validation of Marketing Authorization Application by the European Medicines Agency for ONS-5010 as a Treatment for Wet AMD (GlobeNewswire)
Dec-01-22 08:05AM	Outlook Therapeutics® to Participate in the Cantor Fitzgerald Medical & Aesthetic Dermatology, Ophthalmology & Medtech Conference (GlobeNewswire)
Nov-22-22 08:05AM	Outlook Therapeutics® to Present at the BTIG Ophthalmology Day (GlobeNewswire)
Nov-01-22 09:55AM	Outlook Therapeutics, Inc.'s (NASDAQ:OTLK) top owners are individual investors with 38% stake, while 25% is held by private equity firms (Simply Wall St.)
Oct-28-22 08:05AM	Outlook Therapeutics® Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD (GlobeNewswire) -9.47%
Oct-05-22 06:09AM	Independent Director Kurt Hilzinger Just Bought 33% More Shares In Outlook Therapeutics, Inc. (NASDAQ:OTLK) (Simply Wall St.)
Sep-27-22 08:05AM	Outlook Therapeutics® and AmerisourceBergen Announce Strategic Commercialization Agreement for ONS-5010 for the Treatment of Wet AMD (GlobeNewswire)
Sep-26-22 08:35AM	Outlook Therapeutics® to Present at Eyecelerator @ AAO 2022 (GlobeNewswire)
Sep-07-22 08:05AM	Outlook Therapeutics® to Present at the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Aug-30-22 09:39AM	Outlook Therapeutics Shares Pop After Filing US Application For Its Lead Eye Disease Candidate (Benzinga)
08:05AM	Outlook Therapeutics® Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration (GlobeNewswire)
Aug-15-22 08:05AM	Outlook Therapeutics Strengthens Board of Directors with Appointment of Julia A. Haller, MD (GlobeNewswire)
Aug-10-22 08:05AM	Outlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2022 and Reiterates Key Anticipated Near-Term Milestones (GlobeNewswire)
Aug-04-22 08:05AM	Outlook to Present at the H.C. Wainwright 2nd Annual Ophthalmology Conference (GlobeNewswire)
Jul-26-22 07:18AM	When Will Outlook Therapeutics, Inc. (NASDAQ:OTLK) Become Profitable? (Simply Wall St.)
Jul-05-22 08:05AM	Outlook Therapeutics Announces Full Cash Pre-Payment of Convertible Promissory Note (GlobeNewswire) +7.84%
Jun-14-22 08:05AM	Outlook Therapeutics Confirms Status of Biologics License Application (BLA) Submission for ONS-5010 (GlobeNewswire) +15.95%
May-31-22 08:05AM	Outlook Therapeutics Provides Update on Biologics License Application (BLA) Submission for ONS-5010 as a Treatment for Wet AMD (GlobeNewswire) -31.95%
May-27-22 07:25AM	Bullish Outlook Therapeutics, Inc. (NASDAQ:OTLK) insiders filled their treasuries with US$557k worth of stock over last year (Simply Wall St.) +7.64%
May-18-22 08:05AM	Outlook Therapeutics to Present at the H.C. Wainwright Global Investment Conference (GlobeNewswire) -6.13%
May-13-22 08:05AM	Outlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2022 and Provides Corporate Update (GlobeNewswire) +7.38%
May-10-22 08:35AM	Outlook Therapeutics to Participate in Retina World Congress 2022 (GlobeNewswire)
May-09-22 08:35AM	Outlook Therapeutics to Participate at the Virtual Investor 2022 CEO Spotlight (GlobeNewswire) -7.50%
May-04-22 12:02PM	Here's What Outlook Therapeutics, Inc.'s (NASDAQ:OTLK) Shareholder Ownership Structure Looks Like (Simply Wall St.)
Apr-22-22 08:05AM	BioLexis Reorganization Results in GMS Holdings as Largest Shareholder in Outlook Therapeutics (GlobeNewswire)
Apr-05-22 08:05AM	Outlook Therapeutics to Present at Wet AMD and DME Drug Development Summit (GlobeNewswire)
Apr-04-22 07:45PM	Is Outlook Therapeutics (NASDAQ:OTLK) Using Too Much Debt? (Simply Wall St.)
Mar-31-22 08:05AM	Outlook Therapeutics Submits Biologics License Application to the U.S. Food and Drug Administration for ONS-5010 as a Treatment for Wet AMD (GlobeNewswire) -10.55%
Mar-03-22 08:05AM	Outlook Therapeutics Bolsters Commercialization Expertise with Appointment of Alicia Tozier as Senior Vice President of Marketing and Market Access (GlobeNewswire) +5.29%
Feb-24-22 08:05AM	Outlook Therapeutics to Present at the RANZCO 52nd Annual Scientific Congress (GlobeNewswire) +16.31%
Feb-16-22 10:59AM	When Will Outlook Therapeutics, Inc. (NASDAQ:OTLK) Become Profitable? (Simply Wall St.) +7.14%
Feb-14-22 08:05AM	Outlook Therapeutics Reports Financial Results for First Quarter Fiscal Year 2022 and Provides Corporate Update (GlobeNewswire)
Feb-10-22 08:05AM	Outlook Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference (GlobeNewswire)
Feb-08-22 08:05AM	Outlook Therapeutics Expands Commercial Team with Appointment of Senior Vice President of Commercial Operations (GlobeNewswire)
Feb-02-22 05:38PM	KWB Wealth Buys SPDR Portfolio S&P 600 Small Cap ETF, SPDR Portfolio Short Term Corporate ... (GuruFocus.com) -6.71%
08:05AM	Outlook Therapeutics to Present at the Fourth Annual Telluride Retina Film Festival (GlobeNewswire)
Jan-25-22 08:05AM	Outlook Therapeutics Provides a Corporate Update and Business Outlook (GlobeNewswire)
Jan-19-22 08:05AM	Outlook Therapeutics to Present at the Virtual Investor 2022 Top Picks Conference (GlobeNewswire)
Jan-12-22 10:35AM	JTC Team to Host Virtual Investor 2022 Top Picks Conference on January 25th, 26th, and 27th (ACCESSWIRE)
Jan-04-22 08:35AM	Outlook Therapeutics to Present at the H.C. Wainwright BioConnect Conference (GlobeNewswire)
Dec-22-21 08:05AM	Outlook Therapeutics Reports Financial Results for Fiscal Year 2021 and Provides Corporate Update (GlobeNewswire)
Dec-15-21 08:05AM	Outlook Therapeutics to Present Pivotal Data from NORSE TWO Trial at the 9th International Congress on OCT and OCT Angiography in Rome (ICOOR)/ FLORetina Symposia (GlobeNewswire)
Dec-09-21 08:05AM	Outlook Therapeutics to Present at the 14th Asia-Pacific Vitreo-Retina Society (APVRS) Congress (GlobeNewswire) -6.29%
Nov-29-21 04:15PM	Outlook Therapeutics Announces Closing of $57.5 Million Bought Deal, Including Full Exercise of Underwriters Option to Purchase Additional Shares (GlobeNewswire) +5.11%
Nov-24-21 06:49AM	What Type Of Shareholders Make Up Outlook Therapeutics, Inc.'s (NASDAQ:OTLK) Share Registry? (Simply Wall St.) -18.59%
Nov-23-21 10:30PM	Outlook Therapeutics Increases Previously Announced Bought Deal Offering of Common Stock to $50 Million (GlobeNewswire) +5.41%
04:30PM	Outlook Therapeutics Announces $10 Million Bought Deal Offering of Common Stock (GlobeNewswire)
Nov-13-21 11:00AM	Outlook Therapeutics Presents NORSE TWO Phase 3 Pivotal Safety and Efficacy Data for ONS-5010 / LYTENAVA (bevacizumab-vikg) at the Retina Subspecialty Day, American Academy of Ophthalmology (AAO) 2021 Annual Conference (GlobeNewswire)
Nov-10-21 08:05AM	Outlook Therapeutics to Present at the Virtual Investor Roundtable Event (GlobeNewswire)
Nov-04-21 02:30PM	JTC Team to Host Virtual Investor Roundtable Event on November 16th, 17th, and 18th (ACCESSWIRE)
08:05AM	Outlook Therapeutics to Present at the Retina Subspecialty Day, American Academy of Ophthalmology 2021 Annual Conference (GlobeNewswire)
Nov-03-21 08:05AM	Outlook Therapeutics to Present at the Eyecelerator@AAO 2021 Conference Retina Showcases (GlobeNewswire)
Oct-15-21 08:41AM	11 Best Penny Stocks To Buy According To Hedge Funds (Insider Monkey)
Oct-12-21 12:00PM	Outlook Therapeutics Positive NORSE THREE Safety Data Presented at 2021 American Society of Retina Specialists for ONS-5010 Ophthalmic Bevacizumab (GlobeNewswire)
Oct-07-21 08:05AM	Outlook Therapeutics to Present at the 2021 American Society of Retina Specialists (ASRS) Annual Meeting (GlobeNewswire) +6.70%
Oct-05-21 08:05AM	Outlook Therapeutics to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase (GlobeNewswire)
Sep-28-21 08:05AM	Outlook Therapeutics Reports New Positive 12-Month Safety Data from Pivotal Phase 3 NORSE TWO Trial (GlobeNewswire)
Sep-21-21 08:05AM	Outlook Therapeutics to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference (GlobeNewswire)
Sep-13-21 08:05AM	Outlook Therapeutics Presents Positive NORSE THREE Safety Data for ONS-5010 / LYTENAVA (bevacizumab-vikg) at EURETINA Virtual 2021 Medical Conference (GlobeNewswire)
Sep-08-21 08:05AM	Outlook Therapeutics to Present at H.C. Wainwright 23rd Annual Global Investment Conference (GlobeNewswire)
Aug-26-21 09:57AM	Outlook Therapeutics (NASDAQ:OTLK) shareholder returns have been splendid, earning 198% in 1 year (Simply Wall St.)
Aug-13-21 08:05AM	Outlook Therapeutics Reports Financial Results for Third Quarter of Fiscal Year 2021 and Provides Corporate Update (GlobeNewswire) -5.14%
Aug-11-21 08:05AM	Outlook Therapeutics to Participate at the H.C. Wainwright Ophthalmology Virtual Conference (GlobeNewswire)
Aug-03-21 05:34PM	Why Outlook Therapeutics Stock Surged Today (Motley Fool) +6.64%
07:06AM	Outlook Therapeutics Stock Soars on Positive Results for Eye Treatment (TheStreet.com)

Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. Its pipeline includes unmet patient needs, repackaged IV bevacizumab, and anti-VEGF. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Iselin, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Dagnon Terry	Chief Operations Officer	Apr 20	Sale	1.14	520,000	590,200	653,058	Apr 21 09:05 PM
Evanson Jeff	Chief Commercial Officer	Jan 20	Sale	1.11	267,000	296,370	745,975	Jan 24 08:08 PM
Evanson Jeff	Chief Commercial Officer	Jan 19	Sale	1.22	103,255	125,971	1,012,975	Jan 19 08:05 PM
Evanson Jeff	Chief Commercial Officer	Jan 18	Sale	1.25	33,738	42,172	1,116,230	Jan 19 08:05 PM
Evanson Jeff	Chief Commercial Officer	Jan 17	Sale	1.31	27,162	35,582	1,149,968	Jan 19 08:05 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

OTLK

Outlook Therapeutics Inc

Upgrade your FINVIZ experience